Burning Rock Biotech Limited BNR Schedules Q1 Earnings Release on May 30, 2023 (6700X)
April 27 2023 - 2:00AM
UK Regulatory
TIDMBNR
RNS Number : 6700X
Burning Rock Biotech Limited
27 April 2023
Burning Rock Provides First Quarter 2023 Business Updates and
Schedules Earnings Release on May 30 , 2023
GUANGZHOU, China, April 27, 2023 -Burning Rock Biotech Limited
(NASDAQ: BNR and LSE: BNR, the "Company" or "Burning Rock"), a
company focused on the application of next generation sequencing
(NGS) technology in the field of precision oncology, today
announced that it plans to release its unaudited financial results
for the first quarter of 2023 before the U.S. market opens on May
30, 2023. Following the release, company management will host a
conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the
same day to discuss its financial results for the first quarter of
2023.
While the Company has not completed the preparation of its
financial statements for the first quarter of 2023, it expects to
report a moderately positive revenue growth on a year-over-year
basis, driven by a strong growth rebound in March, reversing the
year-over-year decreasing trend in January-February. Total test
volumes (central-laboratory and in-hospital combined) in March 2023
increased by approximately 29% year-over-year, driven by strong
growth of the in-hospital channel.
Please register in advance of the conference using the link
provided below and dial in 15 minutes prior to the call, using
participant dial-in numbers and unique registrant ID which would be
provided upon registering.
PRE-REGISTER LINK:
https://register.vevent.com/register/BI70acdaea8afc4d3e8f3eec70e5cc3fa7
.
Additionally, a live and archived webcast of the conference call
will also be available on the company's investor relations website
at http://ir.brbiotech.com or through link
https://edge.media-server.com/mmc/p/p3h6zb7y .
A replay of the webcast will be available for 12 months via the
same link above.
Please visit the Company's investor relations website at
https://ir.brbiotech.com/news-events/news-releases on May 30, 2023
to view the earnings release prior to the conference call.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose
mission is to Guard Life via Science, focuses on the application of
next generation sequencing (NGS) technology in the field of
precision oncology. Its business consists of i) NGS-based therapy
selection testing for late-stage cancer patients, and ii) NGS-based
cancer early detection, which has moved beyond proof-of-concept
R&D into the clinical validation stage.
For more information about Burning Rock, please visit:
www.brbiotech.com .
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will", "expect", "anticipates",
"future", "intends", "plans", "believes", "estimates", "target",
"confident" and similar statements. Burning Rock may also make
written or oral forward-looking statements in its periodic reports
to the SEC, in its annual report to shareholders, in press releases
and other written materials and in oral statements made by its
officers, directors or employees to third parties. Statements that
are not historical facts, including statements about Burning Rock's
beliefs and expectations, are forward-looking statements. Such
statements are based upon management's current expectations and
current market and operating conditions, and relate to events that
involve known or unknown risks, uncertainties and other factors,
all of which are difficult to predict and many of which are beyond
Burning Rock's control. Forward-looking statements involve risks,
uncertainties and other factors that could cause actual results to
differ materially from those contained in any such statements. All
information provided in this press release is as of the date of
this press release, and Burning Rock does not undertake any
obligation to update any forward-looking statement as a result of
new information, future events or otherwise, except as required
under applicable law.
Contact: IR@brbiotech.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
QRFEASLXAELDEEA
(END) Dow Jones Newswires
April 27, 2023 02:00 ET (06:00 GMT)
Burning Rock Biotech (LSE:BNR)
Historical Stock Chart
From Apr 2024 to May 2024
Burning Rock Biotech (LSE:BNR)
Historical Stock Chart
From May 2023 to May 2024